Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults, and improves quality of life.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑supported distribution across multiple regions, including compliance with EU pharmacopoeial specifications.

Mirabegron is used to manage symptoms of the overactive bladder syndrome.

- Overactive bladder: improves bladder capacity and reduces urgency and frequency episodes. - Urinary urgency: decreases the number of sudden urges to void. - Urge urinary incontinence: lessens involuntary leakage episodes.

Mirabegron may be associated with several adverse reactions.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: occasional mild to moderate headache. - Constipation: reduced bowel motility leading to hard stools. - Dry mouth: decreased salivary secretion. - Urinary tract infection: bacterial infection of the urinary system.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: markedly high blood pressure requiring medical attention. - Angioedema: swelling of face, lips, or throat. - Tachycardia: rapid heart rate. - Allergic reactions: rash, itching, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible individuals.

Before prescribing Mirabegron, clinicians should consider several precautionary measures.

- Assess blood pressure: measure baseline and monitor regularly. - Monitor for urinary retention: watch for signs of incomplete bladder emptying. - Evaluate renal function: adjust use in patients with impaired kidneys. - Use caution in uncontrolled hypertension: avoid initiation if blood pressure is not controlled. - Avoid in patients with known hypersensitivity to mirabegron or excipients. - Store at room temperature: keep in the original pack, protect from moisture and light.

Mirabegron can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - Combined anticholinergics: risk of increased urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics: additive effect on blood pressure. - Antihypertensives: potential for excessive blood pressure lowering. - NSAIDs: may affect renal function when used together.